Provider: View Press Release
Type: Link
Title: GSK to highlight continued progress in oncology pipeline and portfolio with data presented at ESMO | GSK
Description: The data reflects our commitment to strengthening our oncology pipeline across immuno-oncology, synthetic lethality & oncology cell therapy
Provider: View Press Release
Type: Link
Title: GSK Consumer Healthcare leads oral care industry with launch of its first carbon neutral toothbrush | GSK
Description: 73% of consumers say they would definitely change their consumption habits to reduce their environmental impact.
Provider: View Press Release
Type: Link
Title: SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate | GSK
Description: Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
Provider: View Press Release
Type: Link
Title: GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours | GSK
Description: GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumours
Provider: View Press Release
Type: Link
Title: Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study | GSK
Description: Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone
Provider: View Press Release
Type: Link
Title: GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps | GSK
Description: Fourth indication for mepolizumab in the US for eosinophil-driven diseases.